117
Views
20
CrossRef citations to date
0
Altmetric
Original Research

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment

, , &
Pages 1877-1885 | Published online: 26 Sep 2018

Abstract

Purpose

To determine the levels of interleukin (IL)-6, vascular endothelial growth factor-A, platelet-derived growth factor, placental growth factor (PLGF), and other cytokines in the aqueous fluid of patients with neovascular age-related macular degeneration who respond poorly to ranibizumab.

Patients and methods

This is an observational, prospective study. Thirty-two eyes from 30 patients were included in the study: 11 patients who responded poorly to ranibizumab and were switched to aflibercept (AF group), 8 patients who received ranibizumab and photodynamic therapy (PDT group), and 13 patients who responded to ranibizumab (control group). Aqueous fluid samples were collected for analysis of cytokine levels at baseline and after 1, 2, and 3 months of treatment. The effect of treatment on cytokine levels was compared between the study groups and between different time points using a linear mixed-effect regression model.

Results

In the AF group, there was an increase in vascular endothelial growth factor-C, IL-7, and angiopoeitin-2 levels (P=0.01) and a decrease in intercellular adhesion molecule and IL-17 levels (P=0.01) between baseline and 3 months. After adjustment for age, sex, race, and type of lesion at baseline, the PLGF level was higher (P=0.02) and the IL-7 level was lower (P=0.04) in the ranibizumab non-responder group than in the ranibizumab responder group.

Conclusion

Switching from ranibizumab to aflibercept did not reduce intraocular levels of angiogenesis cytokines, but resulted in improvement of central subfield thickness. PLGF levels were higher in poor responders to ranibizumab. The response of lesions to medication might be related to the stage of choroidal neovascularization.

Trial registration

www.ClinicalTrial.gov (NCT02218177c).

Introduction

Wet age-related macular degeneration (AMD) is one of the leading causes of blindness in adults and its pathogenesis is characterized by choroidal neovascularization (CNV).Citation1,Citation2 Ranibizumab (Lucentis®; Genentech Inc./Novartis, San Francisco, CA, USA) has been approved for the treatment of AMD since 2006. It is a recombinant, humanized, monoclonal antibody antigen-binding fragment that inhibits active forms of vascular endothelial growth factor (VEGF)-A isoform and was shown to improve mean visual acuity (VA) in eyes with neovascular AMD in the MARINA and ANCHOR studies.Citation3Citation5 Since then, ranibizumab has become one of the current standards for treatment of CNV secondary to AMD.

Intraocular growth factors and cytokines, such as VEGF, pigment epithelium-derived factor, and interleukin (IL)-6, have been found to play an important role in the development of CNV. VEGF and pigment epithelium-derived factor have been reported to be increased in patients with CNV secondary to AMD; reduction of these cytokines is correlated with anatomic improvement in the macula.Citation6Citation8 IL-6 is a proinflammatory cytokine that was found to be increased in the serum and aqueous humor of patients with neovascular AMD.Citation9 Placental growth factor (PLGF) is a member of the VEGF family, which has been found to be induced during the early stages of angiogenesis in vivo and in vitro. Aflibercept (VEGF Trap; Bayer AG, Leverkusen, Germany; Regeneron, Tarrytown, NY, USA) is a recombinant soluble VEGF receptor protein that has a high affinity for all VEGF isoforms and for PLGF.Citation10 The VIEW 1 and VIEW 2 studies showed non-inferiority and clinical equivalence of aflibercept to monthly ranibizumab in the treatment of wet AMD,Citation11 with an average of five fewer injections at 96 weeks of treatment.Citation12 Aflibercept has been reported to be a treatment option for patients who are refractory to ranibizumab and bevacizumab.Citation13Citation16

Historically, photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis International AG, Basel, Switzerland) was the standard treatment for neovascular AMD before the approval of anti-VEGF.Citation17 The VIP study reported that PDT significantly reduced the risk of moderate and severe visual loss in classic CNV and recommended PDT for patients with AMD and subfoveal lesions.Citation18 Combination therapy of PDT and ranibizumab improved VA, reduced central retinal thickness, and decreased CNV leakage on fluorescein angiography.Citation19Citation21 This combination treatment has also been used as a rescue therapy in patients with AMD who fail anti-VEGF monotherapy.Citation22

Approximately 1%–10% of patients with CNV secondary to AMD have a poor response to ranibizumab.Citation23,Citation24 The mechanisms of resistance to intravitreal ranibizumab can be categorized as non-response, development of tolerance, or tachyphylaxis. Poor response to treatment with intravitreal ranibizumab can also stem from misdiagnosis of the disease or its complications, such as tears of the retinal pigment epithelium, retinal detachment, and macular scarring. Changes in the choroidal neovascular membrane, such as increased fibrosis, changes in the type of CNV lesion, chronic changes in vessel permeability, and changes in the photoreceptors and retinal pigment epithelium are possible mechanisms for a reduced drug response in AMD.Citation24 Moreover, increased expression of VEGF because of increased number of macrophages in CNVCitation25 or change in signal transduction, such as polymorphism of the VEGF receptor (VEGF2/KDR) gene, has been reported to influence the response of neovascular AMD to treatment with ranibizumab.Citation26

The objective of this study was to determine the levels of IL-6, VEGF, PLGF, and other cytokines in the aqueous humor of patients with AMD who are resistant or poor responders to treatment with ranibizumab.

Patients and methods

This prospective study was conducted at the Toronto Western Hospital, University Health Network, Toronto, ON, Canada, according to the tenets of the Declaration of Helsinki. The study protocol was approved by the University Health Network Research Ethics Board (approval number 13-6849-AE). The study was also registered on www.ClinicalTrial.gov (NCT02218177c). Written informed consent was obtained from all patients who participated in the study.

Inclusion/exclusion criteria

Patients were included in the study if they had a diagnosis of neovascular AMD, were over the age of 50 years, had previously been treated with ranibizumab, and could be classified as responders or poor responders.

Poor responders were defined as patients who received ranibizumab and had one or more of the following clinical features after at least six consecutive monthly 0.05 mg/0.05 mL ranibizumab injections:

  • Increased central subfield thickness (CST) or persistent intraretinal/subretinal fluid documented by spectral-domain optical coherence tomography (OCT)

  • Evidence of persistent leakage on fluorescein angiography

  • Worsening of best-corrected VA of more than 5 Early Treatment Diabetic Retinopathy Study letters.

Responders were defined as patients who were treated with monthly ranibizumab with at least three consecutive 0.05 mg/0.05 mL ranibizumab injections and had the following:

  • An increase or maintenance of VA during follow-up; evidence of improvement in CST or a reduction in intraretinal/subretinal fluid on spectral-domain OCT

  • No improvement in VA, but otherwise remaining stable or losing not more than 5 Early Treatment Diabetic Retinopathy Study letters with evidence of improvement in CST or a reduction in intraretinal/subretinal fluid on spectral-domain OCT

  • Improved leakage on fluorescein angiography.

Patients were excluded if they were uncooperative with intravitreal treatment, had received PDT treatment in the previous 6 months, had clinically active ocular inflammation, had received ocular treatment with an immunosuppressive agent within the previous 3 months, or were currently receiving systemic anti-VEGF medication or immunosuppressive agents.

Study groups

There were three treatment groups in the study. The first group consisted of poor responders to ranibizumab who switched to a combination of ranibizumab and PDT (PDT group; Supplementary material). An aqueous tap was performed before injection of dexamethasone and before the second, third, and fourth ranibizumab injections. The second group consisted of non-responders to ranibizumab who switched to monthly intravitreal aflibercept (AF group). Aqueous samples were collected by anterior chamber paracentesis before each injection of aflibercept. The third group consisted of controls who were classified as ranibizumab responder. The responder group was treated with a treat-and-extend protocol. Samples of aqueous humor were taken before each intravitreal ranibizumab injection at the baseline visit (after enrollment) and at visits 1, 2, and 3 months later. The aqueous sampling methods are shown in Supplementary material.

Cytokine assays

The analysis was done at the Princess Margaret Genomics Center, Toronto, ON, Canada. Inflammatory cytokines were analyzed using Luminex xMAP technology (Bio-Rad Laboratories Inc., Hercules, CA, USA) with Milliplex® MAP Human cytokine/Angiogenesis/Growth factor and a Cardiovascular Magnetic Bead Panel Immunology Multiplex assay (EMD Millipore, Billerica, MA, USA). The cytokines analyzed included IL-1A, IL-1B, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p40, IL12p70, IL-13, IL-17A, platelet-derived growth factor-AA, tumor necrosis factor alpha (TNF-α), TNF-β, monocyte chemoattractant protein (MCP)-1, MCP-3, intercellular adhesion molecule (ICAM)-1, PLGF, VEGF-A, VEGF-C, VEGF-D, angio-poeitin-2, bone morphogenetic protein-9, epidermal growth factor (EGF), endothelin, fibroblast growth factor (FGF)-1, FGF-2, follistatin, granulocyte colony-stimulating factor, heparin-binding EGF-like growth factor, hepatocyte growth factor (HGF), and leptin.

Estimation of limits of detection

Several of the cytokines had lower limits of detection (LODs). A literature search identified a number of simple methods that involve replacing the missing LOD data with constants, such as structural zeros (cytokine absent) or LOD/22. However, imputation of values exceeding the LODs (in our case, lower than the lower LOD) is likely to result in artificially reduced SDs and increase the chance of type one error. Therefore, we developed an approach to estimate the values censored by the LODs that uses gamma distributions, the parameters (shape and scale) of which were estimated based on data at handCitation27 (values above the lower LOD), and then using Monte Carlo simulationCitation28 to sample values that were lower than the lower LOD. illustrates this process for the VEGF-C cytokine. The gray region on the histogram of VEGF-C represents values below the LOD. By sampling the gamma distribution in this range, a more realistic sample of VEGF-C values below the LOD can be obtained.

Figure 1 Histogram of gamma distribution range and prediction values below LOD of VEGF-C.

Abbreviations: LOD, limit of detection; VEGF, vascular endothelial growth factor.
Figure 1 Histogram of gamma distribution range and prediction values below LOD of VEGF-C.

Statistical analysis

The baseline data are shown as the mean and SD for continuous variables and as the count and percentage for categorical variables. Before formal modeling of each cytokine, we used propensity score adjustment of the baseline characteristics in an attempt to balance potentially confounding effects between the control, PDT, and AF groups. Given that there were three study groups, we could not use a standard approach for propensity score adjustment and instead used the propensity score adjustment method devised by McCaffrey et al.Citation29 This method uses boosted logistic regression to generate propensity scores across three or more groups. After obtaining propensity scores, within- and between-subject effects were modeled using linear mixed-effect regression. Finally, we investigated the potential utility of levels of the cytokines of interest to identify patients who are not responding to therapy. First, we used a random forests feature selection process to identify the best subset of cytokines for discriminating between responders and poor responders. The analysis was performed using the R statistical package (version 3.2.4, R: A language and environment for statistical computing, 2016; R Foundation for Statistical Computing, Vienna, Austria), propensity score adjustment was performed using the R library twang,Citation30 and variable selection was performed using the R library varSelRF.Citation31 A P-value of 0.05 was considered statistically significant.

Results

Thirty-two eyes from 30 patients were included in the study from June 2014 to October 2015. The control group, combination ranibizumab/PDT group, and AF group contained 13, 8, and 11 eyes, respectively. The baseline demographic data are shown in . One Asian patient in the AF group was diagnosed with polypoidal choroidal vasculopathy that was confirmed on indocyanine green angiography.

Table 1 Baseline demographic data

Thirty-seven cytokines was analyzed, of which only PLGF, VEGF-A, VEGF-C, angiopoeitin-2, EGF, endothelin-1, follistatin, granulocyte colony-stimulating factor, heparin-binding EGF-like growth factor, HGF, leptin, ICAM-1, IL-3, IL-6, IL-7, IL-8, IL-17, MCP-1, TNF-α, and platelet-derived growth factor were included in the statistical analysis and interpretation; the other cytokines could not be interpreted because of their extremely low LOD. Mean cytokine levels at baseline are shown in Table S1.

The mean changes in aqueous cytokine levels from baseline to month 3 in the control group, PDT group, and AF group are shown in .

Table 2 Mean changes in cytokines levels (pg/dL) from baseline to visit 3

Clinical responses to switching treatment

The VA in each visit is shown in . In the control group, the mean improvement in VA from baseline to month 2 was 0.15 logMAR (P=0.02, 95% CI 0.01–0.29) and from baseline to month 3 was 0.14 logMAR (95% CI 0.01–0.28). The mean improvement in VA from baseline to month 3 was 0.01 logMAR (95% CI −0.24 to 0.21) and 0.03 logMAR (95% CI −0.24 to 0.17) in the PDT/ranibizumab group and aflibercept group, respectively. There was no statistically significant reduction in CST from baseline to month 3 in the control group (−2.36 μm; 95% CI −43.49 to 38.75) or in the aflibercept group (−43.4 μm, 95% CI −104.4 to 17.5). There was a significant mean change in CST from baseline to month 3 in the PDT group of −77.5 μm (95% CI −148 to −7.0). After adding PDT to ranibizumab, six of eight patients (75%) in the PDT group showed stabilization or improvement in AMD activity, while two patients showed persistence of subretinal fluid and a reduction in VA from baseline to month 3 (0.45 and 0.16 logMAR), but no new hemorrhage or signs of new choroidal neovascular membrane (CNVM). In the aflibercept group, eight of eleven patients (72%) showed stabilization and improvement of VA and anatomic outcomes from baseline to month 3. Three patients showed a reduction in VA (0.12, 0.16, and 0.1 logMAR), but a nonsignificant reduction of CST of 269 μm at month 2 (no OCT data were available at month 3) and 53 and 0.9 μm at month 3. None of these patients showed an increase in CST. One patient showed a marked reduction in CST (–266 μm) with improvement of VA of 0.3 logMAR after three injections.

Table 3 Mean visual acuity of patient in each study group

Responders vs poor responders

After adjustment for age, sex, race, and type of lesion at the baseline visit, the PLGF level was higher in the non-responder group than in the responder group, with a mean difference of 474.30 pg/dL (95% CI 54.11–894.4, P=0.02). In contrast, the IL-7 level was lower in the non-responder group, with a mean difference of 0.8 pg/dL (95% CI −1.58 to −0.03, P=0.04). There was no statistically significant difference in the levels of the other cytokines between the responder group and the non-responder group.

Discussion

In this study, we found that levels of PLGF were significantly higher in patients who responded poorly to ranibizumab than in those who responded to ranibizumab. PLGF levels were also lower than the levels in the group that received PDT and AF. PLGF, flt-1, and the VEGFR-1 receptor have been found to be expressed on the human neovascular membrane. PLGF mRNA expression is also upregulated during development of CNV.Citation32 Neutralization of the PLGF receptor can reduce the formation of CNV.Citation32 Ranibizumab is an affinity-matured antigen-binding fragment (Fab) with high affinity for VEGF-A and neutralizes all human VEGF-A isoforms, except for PLGF.Citation33,Citation34 Our finding of an increase in the PLGF level in patients who did not respond to ranibizumab mono-therapy is consistent with the evidence of multiple cytokines being involved in the development of CNV.

The current study also found that the levels of VEGF-A and PLGF, which play an important role in angiogenesis, were reduced after switching treatment to a combination of PDT and AF, albeit not significantly so. The present findings are consistent with the previous report of an additional effect of anti-PLGF in the reduction of subfoveal thickness on OCT and fluid activity after switching treatment from ranibizumab/bevacizumab to aflibercept in persistent fluid of exudative AMD.Citation13,Citation14 However, similar to other studies, the VA did not improve after switching treatment. In this study, there was a reduction of CST in the AF group, but this was not statistically significant. There was also no significant change in VA in three patients in the AF group, despite anatomic improvement; their VA was reduced. According to the Macular Photocoagulation Study Group, repeat measurement of VA in patients with AMD and poor VA (<20/100) has low reliability when compared with that in patients with better VA. The reduction in VA despite anatomic improvement in this study could reflect the large variation in VA measurements in poor vision patient.Citation35 The chronicity of CNV activity has also been reported to result in a poor gain in VA despite successful anatomic treatment after switching from ranibizumab to aflibercept in refractory cases.Citation36,Citation37 Funk et al studied the change in aqueous VEGF of ranibizumab in AMD from baseline to 12 months follow-up; the level of VEGF was markedly reduced after the first treatment injection and was below the level of detection after repeated treatment.Citation7

In our study, the control group was treated with ranibizumab and demonstrated favorable response. The lower levels of VEGF and lower than LODs might also mask the change in aqueous VEGF in the control group. In our study, IL-7 level was lower in the poor responder group. IL-7 stimulates the proliferation of B-cell progenitors, mature T-cells, and thymocytes via the high-affinity hematopoietin receptor (IL-7R).Citation38 IL-7 also has a role in the enhancement of homeostatic proliferation and prolonged survival of naïve T-cells,Citation39 and inhibition of IL-7 is used in the treatment of patients with lymphopenia.Citation40 IL-7 was found to support both T-cells and B-cells in exacerbating the non-T/non-B-cell–mediated chronic inflammatory response.Citation41 Upregulation of ICAM-1 can also lead to development of CNV.Citation42 The presence of surface expression levels of ICAM-1 is associated with increased levels of IL-1 and IL-7.Citation43 Fauser et al studied cytokine levels in the aqueous humor of eyes with naïve AMD that underwent cataract surgery or treatment with ranibizumab and reported elevation of MCP-1 and VCAM in the patients with neovascular AMD when compared with controls.Citation44 IL-8 and MCP-1 have been found to promote angiogenesis via accumulation of macrophages that release angiogenic promoters and degrade Bruch’s membrane.Citation45 Grossniklaus et al studied surgically excised subfoveal CNV specimens from an eye bank and found that VEGF tissue factor and MCP-1 expression levels were higher in specimens with “inflammatory active” CNV than in those with fibrotic “inflammatory inactive” CNV. The MCP-1 and VEGF are high during the active stage of CNV and minimal in fibrotic matured CNV.Citation25 The reduction in IL-7 in our non-responder group might reflect a fibrotic stage of CNV. In our study, the significant reduction of ICAM-1 in the AF group likely reflected the decreased activity of CNV after switching medication.

In this study, we found a significant decrease in leptin and IL-6 levels after PDT. This can be explained by the regression of CNV that occurs in response to PDT.Citation46,Citation47 Leptin has been found to regulate the tyrosine kinase-dependent intracellular pathway and to stimulate angiogenesis via the leptin receptor (Ob-R).Citation48,Citation49 Immunohistochemical analysis of CNV membrane tissue revealed leptin staining and absence of leptin staining in normal posterior segment tissue.Citation50 IL-6 is a pleiotropic cytokine involved in the acute inflammatory phase of wound healing, fibrogenesis, angiogenesis, and is associated with CNV activity.Citation51Citation53 Anti-VEGF monotherapy limits leakage and inhibits vessel growth without complete and sustained resolution of CNV. In the FocusCitation54 and CLOVERCitation55 studies, the combination of therapy of ranibizumab and PDT improved VA, reduced angiogenesis, and extended the fluid-free interval. In our study, we also showed adding PDT to treatment in non-responders helped in the regression of CNV and in downregulation of the cytokines involved in angiogenesis.

In our study, VEGF-C, angiopoeitin-2, and HGF levels were elevated in the AF group. The angiopoeitin-2 in the CNV membrane stimulates the initial angiogenic response of blood vessels. Angiopoeitin-1 and angiopoeitin-2 were found to be promoters of the VEGF gene and to regulate expression of VEGF through the MAPK pathway. Hera et al reported that in 18 CNV membranes secondary from AMD showed low expression of VEGF-A and that expression of this cytokine correlated with the activity of CNV. HGF has been reported to be increased in retinopathy of prematurityCitation56 and retinal detachment,Citation57 and is induced by FGF-2.Citation58 The possible role of HGF in angiogenesis via expression of urokinase has been studied in a mouse model.Citation58 HGF has been identified as an angiogenic factor found in corneal wound healing, tear, aqueous humor, and vitreous humor and found to increase in proliferative diabetic retinopathy.Citation59 Therefore, the elevation of HGF levels from baseline in the AF group in our study was likely related to the persistent activity of the CNV.

One strength of our study is its prospective design, whereby aqueous humor was collected at the time of the intraocular injections. Analysis of the results for cytokines involved in angiogenesis and inflammation will aid our understanding of the pathogenesis of neovascular AMD in patients who respond poorly to treatment. The finding of elevated angiopoeitin-2 levels in non-responders in our AF group suggests a potential benefit from using anti-angiopoietin medication in current clinical studies. IL-17 might be important in the pharmacologic treatment of neovascular AMD.

There are some limitations to this study, including the cytokine analysis being performed in patients who had previously received treatment, which may have altered the baseline cytokine profile. In addition, this study had a relatively small sample size, so we were unable to test the external validity of our prediction model of response to therapy based on cytokine levels. The follow-up visit in ranibizumab responders utilizes a treat-and-extend protocol which might influence the cytokine activity.

The results of this study will aid in our understanding of the role of cytokines in the response of patients to treatment with ranibizumab. In the future, larger studies examining changes in cytokine levels may help to clarify whether some cytokines can be biomarkers that identify poor responders and guide the selection of treatment for these patients.

Data sharing statement

The datasets generated and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

Author contributions

All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Acknowledgments

This study was funded by the Global Ophthalmology Award Program (Bayer Pharmaceuticals Inc.). The funding organization did not have any role in the design or conduct of this research.

This study was presented as a poster at the ARVO 2017 annual meeting, Baltimore, USA.

Supplementary material

Photodynamic therapy procedure

Verteporfin photodynamic therapy (PDT) was administered to the leakage area in fluorescein angiography with a full fluence (50 J/cm2) and a light delivery time for 83 seconds. At ~1 hour after PDT, dexamethasone 200 μg/0.05 mL was injected intravitreally, and 1 week later, the patient received intravitreal ranibizumab 0.5 mg/0.05 mL. Subsequently, the patient received monthly injections of ranibizumab.

Aqueous sampling through anterior chamber paracentesis

Topical 0.5% tetracaine hydrochloride was applied before the procedure and a wire speculum was used. A sterile cotton tip soaked in 10% povidone iodine was applied at the sites of the aqueous tap and the intravitreal injection. A sterile unplugged 0.1 mL syringe with a 30 G needle was placed at the limbus parallel to the iris plane. Aqueous fluid (0.05 mL) was removed by passive pressure. Intravitreous injection of either ranibizumab or aflibercept was administered promptly afterward. The aqueous fluid was placed in 0.2 mL PCR tubes and stored at −80°C. All aqueous fluid samples were analyzed at the end of the study.

Table S1 Mean and range of cytokine level (pg/dL) at baseline visit

Disclosure

The authors report no conflicts of interest in this work.

References

  • WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
  • PascoliniDMariottiSPGlobal estimates of visual impairment: 2010Br J Ophthalmol201296561461822133988
  • RofaghaSBhisitkulRBBoyerDSSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
  • RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
  • BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
  • MuetherPSHermannMMViebahnUKirchhofBFauserSVascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumabOphthalmology2012119102082208622920670
  • FunkMKarlDGeorgopoulosMNeovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumabOphthalmology2009116122393239919815292
  • AhnJKMoonHJChanges in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degenerationAm J Ophthalmol20091485e711718724
  • Izumi-NagaiKNagaiNOzawaYInterleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationAm J Pathol200717062149215817525280
  • HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
  • HeierJSBrownDMChongVIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
  • Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
  • ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol20139781032103523766432
  • KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
  • BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol20131561152223706500
  • WykoffCCBrownDMMaldonadoMECroftDEAflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)Br J Ophthalmol201498795195524518078
  • MillerJWSchmidt-ErfurthUSickenbergMPhotodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a Phase 1 and 2 studyArch Ophthalmol199911791161117310496388
  • Verteporfin in Photodynamic Therapy Study GroupVerteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2Am J Ophthalmol2001131554156011336929
  • Wolf-SchnurrbuschUEBrinkmannCKBergerLWolfSEffects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degenerationActa Ophthalmol201189658559019878113
  • SpielbergLLeysATreatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 yearsGraefes Arch Clin Exp Ophthalmol2010248794395620204659
  • Schmidt-ErfurthUWolfSPROTECT Study GroupSame-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degenerationBr J Ophthalmol200892121628163518772178
  • TozerKRChongLSaddaSRRescue Therapy With Combined Anti-vegf And Pdt For Refractory AMDInvestigative Ophthalmology & Visual Science20115214167120926815
  • EghøjMSSørensenTLTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumabBr J Ophthalmol2012961212321733918
  • BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?20121222157632
  • GrossniklausHELingJXWallaceTMMacrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularizationMol Vis2002811912611979237
  • HermannMMvan AstenFMuetherPSPolymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degenerationOphthalmology2014121490591024365177
  • CoxNJWarburtonJArmstrongAHollidayVJFitting concentration and load rating curves with generalized linear modelsEarth Surf Process Landf20083312539
  • RobertCPMonte Carlo MethodsWileyOnline Library2004
  • MccaffreyDFRidgewayGMorralARPropensity score estimation with boosted regression for evaluating causal effects in observational studiesPsychol Methods20049440342515598095
  • BurgetteLGriffinBAMccaffreyDPropensity scores for multiple treatments: a tutorial for the mnps function in the twang packageR Package Rand Corporation2016
  • Díaz-UriarteRAlvarez de AndrésSGene selection and classification of microarray data using random forestBMC Bioinformatics20067316398926
  • RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
  • FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
  • ChenYWiesmannCFuhGSelection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigenJ Mol Biol1999293486588110543973
  • BlackhurstDWMaguireMGReproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study GroupRetina1989931631692480626
  • MuetherPSHoersterRHermannMMKirchhofBFauserSLong-term effects of ranibizumab treatment delay in neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2013251245345822573410
  • de MassougnesSDiraniAAmbresinAPigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effectsRetina201636588188827115852
  • PeschonJJMorrisseyPJGrabsteinKHEarly lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient miceJ Exp Med19941805195519607964471
  • TanJTDudlELeRoyEIL-7 is critical for homeostatic proliferation and survival of naive T cellsProc Natl Acad Sci U S A200198158732873711447288
  • RosenbergSASportèsCAhmadzadehMIL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cellsJ Immunother200629331331916699374
  • von Freeden-JeffryUDavidsonNWilerRFortMBurdachSMurrayRIL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitisJ Immunol199816110567356809820548
  • SakuraiETaguchiHAnandATargeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularizationInvest Ophthalmol Vis Sci20034462743274912766082
  • DennigDLacerdaJYanYGasparettoCO’ReillyRJICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7Cell Immunol199415624144237912996
  • FauserSViebahnUMuetherPSIntraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degenerationActa Ophthalmol201593873473826016605
  • HigginsGTWangJHDockeryPClearyPERedmondHPInduction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segmentsInvest Ophthalmol Vis Sci20034441775178212657621
  • Schlötzer-SchrehardtUViestenzANaumannGOLaquaHMichelsSSchmidt-ErfurthUDose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyesGraefes Arch Clin Exp Ophthalmol2002240974875712271373
  • BresslerNMTreatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2Arch Ophthalmol2001119219820711176980
  • ParkHYKwonHMLimHJPotential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitroExp Mol Med20013329510211460888
  • BouloumiéADrexlerHCLafontanMBusseRLeptin, the product of Ob gene, promotes angiogenesisCirc Res19988310105910669815153
  • CuiJZHornanDPotterMJThe role of leptin in choroidal neovascularizationAm J Ophthalmol2001132579279411704049
  • BarnesTCAndersonMEMootsRJThe many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosisInt J Rheumatol20112011721608621941555
  • RohMIKimHSSongJHLimJBKohHJKwonOWConcentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with and after bevacizumab treatmentRetina200929452352919262441
  • Izumi-NagaiKNagaiNOzawaYInterleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationAm J Pathol200717062149215817525280
  • LanzettaPGroup FSCombination intravitreal ranibizumab 0.5 mg and verteporfin PDT versus verteporfin PDT alone in the FOCUS study of neovascular age-related macular degeneration (AMD)Invest Ophthalmol Vis Sci2007482869
  • LarsenBDavisMMudvariSCombination Lucentis and Ocular Photodynamic Therapy with Visudyne, with Evaluation-Based Retreatments (CLOVER) TrialInvest Ophthalmol Vis Sci201051902
  • LashkariKHiroseTYazdanyJMcMeelJWKazlauskasARahimiNVascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurityAm J Pathol200015641337134410751359
  • JinMChenYHeSRyanSJHintonDRHepatocyte growth factor and its role in the pathogenesis of retinal detachmentInvest Ophthalmol Vis Sci200445132332914691191
  • NaldiniLVignaENarsimhanRPHepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-METOncogene1991645015041827664
  • GriersonIHeathcoteLHiscottPHepatocyte growth factor/scatter factor in the eyeProg Retin Eye Res200019677980211029554